ROLPH TIMOTHY (Chief Scientific Officer) sold 7.0% of their position (12.50K shares) of AKERO THERAPEUTICS, INC. on the open market
Open‑market sale worth $576.0K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 10/9/2025ACC: 0001193125-25-236152
Officer· Chief Scientific Officer
Since Jun 2019
-12.50K
Net shares
Net seller
$576.0K
Total sold
2
Open market trades
0B · 2S
4
Total transactions
12.50K acquired · 25K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
+12.50K
Price / share
$28.35
Trade value
$354.38K
% of position
7.5%
10/7/2025
166.57K→179.07K
Common Stock
Direct
Shares
−11.46K
Price / share
$46.01
Trade value
$527.45K
% of position
6.4%
10/7/2025
179.07K→167.61K
Common Stock
Direct
Shares
−1.04K
Price / share
$46.82
Trade value
$48.55K
% of position
0.6%
10/7/2025
167.61K→166.57K
Total
Net shares
+0.00
Net value
-$221.63K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 10/7/2025 | M · Option Exercise | +12.50K | $28.35 | $354.38K | 7.5% | 166.57K | 179.07K |
| Common Stock Direct | 10/7/2025 | S · Sale | −11.46K | $46.01 | $527.45K | 6.4% | 179.07K | 167.61K |
| Common Stock Direct | 10/7/2025 | S · Sale | −1.04K | $46.82 | $48.55K | 0.6% | 167.61K | 166.57K |
| Total | +0.00 | -$221.63K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
12.50K shares
Shares
−12.50K
Strike price
28.35
Held after
49.95K
Exercisable
—
10/7/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock12.50K shares | 10/7/2025 | M · Option Exercise | −12.50K | 28.35 | — | 49.95K |